Do analysts rate PRTC or AMLX?

Amylyx Pharmaceuticals has a consensus target price of $23.00, suggesting a potential upside of 40.50%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Amylyx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90

Which has higher earnings and valuation, PRTC or AMLX?

PureTech Health has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Amylyx Pharmaceuticals $87.37M 20.83 -$144.74M -$1.50 N/A

Is PRTC or AMLX more profitable?

PureTech Health's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health N/A N/A N/A Amylyx Pharmaceuticals N/A -55.69% -50.73%

Does the media favor PRTC or AMLX?

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Amylyx Pharmaceuticals and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Amylyx Pharmaceuticals' score of 0.00 indicating that PureTech Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PVLA or PRTC?

Palvella Therapeutics currently has a consensus price target of $199.53, indicating a potential upside of 68.13%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Palvella Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palvella Therapeutics 1 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.94 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, PVLA or PRTC?

Palvella Therapeutics has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Palvella Therapeutics $42.81M 39.75 -$41.72M -$4.17 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is PVLA or PRTC more profitable?

PureTech Health's return on equity of 0.00% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -56.87% -42.50% PureTech Health N/A N/A N/A

Does the media favor PVLA or PRTC?

In the previous week, Palvella Therapeutics had 6 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Palvella Therapeutics and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Palvella Therapeutics' score of 0.46 indicating that PureTech Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SRPT or PRTC?

Sarepta Therapeutics presently has a consensus target price of $24.81, indicating a potential upside of 43.74%. Given Sarepta Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Sarepta Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 6 Sell rating(s) 10 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.08 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, SRPT or PRTC?

PureTech Health has lower revenue, but higher earnings than Sarepta Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sarepta Therapeutics $2.20B 0.83 -$713.41M -$0.96 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Does the media favor SRPT or PRTC?

In the previous week, Sarepta Therapeutics had 2 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Sarepta Therapeutics and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Sarepta Therapeutics' score of 0.61 indicating that PureTech Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, SNDX or PRTC?

PureTech Health has lower revenue, but higher earnings than Syndax Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Syndax Pharmaceuticals $172.35M 10.08 -$285.42M -$2.79 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Does the media prefer SNDX or PRTC?

In the previous week, Syndax Pharmaceuticals had 5 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 1 mentions for PureTech Health. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat PureTech Health's score of 0.72 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SEPN or PRTC?

Septerna currently has a consensus target price of $45.78, suggesting a potential upside of 25.18%. Given Septerna's stronger consensus rating and higher possible upside, research analysts plainly believe Septerna is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, SEPN or PRTC?

Septerna has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $72.26M 22.81 -$48.88M -$0.81 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Does the media prefer SEPN or PRTC?

In the previous week, Septerna had 2 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Septerna and 1 mentions for PureTech Health. Septerna's average media sentiment score of 1.16 beat PureTech Health's score of 0.72 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PureTech Health (PRTC) Competitors

$17.42 0.00 (0.00%)

As of 06/22/2026

Compare

PRTC vs. AMLX, PVLA, SRPT, SNDX, and SEPN

Should you buy PureTech Health stock or one of its competitors? MarketBeat compares PureTech Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PureTech Health include Amylyx Pharmaceuticals (AMLX), Palvella Therapeutics (PVLA), Sarepta Therapeutics (SRPT), Syndax Pharmaceuticals (SNDX), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry.

How does PureTech Health compare to Amylyx Pharmaceuticals?

PureTech Health (NASDAQ:PRTC) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Amylyx Pharmaceuticals and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Amylyx Pharmaceuticals' score of 0.00 indicating that PureTech Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PureTech Health's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Amylyx Pharmaceuticals has a consensus target price of $23.00, suggesting a potential upside of 40.50%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

PureTech Health has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.16, meaning that its share price is 116% less volatile than the broader market.

PureTech Health has higher earnings, but lower revenue than Amylyx Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Amylyx Pharmaceuticals	$87.37M	20.83	-$144.74M	-$1.50	N/A

Summary

Amylyx Pharmaceuticals beats PureTech Health on 8 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

PureTech Health's return on equity of 0.00% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
PureTech Health	N/A	N/A	N/A

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Palvella Therapeutics has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	39.75	-$41.72M	-$4.17	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Palvella Therapeutics has a beta of -0.15, indicating that its stock price is 115% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Palvella Therapeutics currently has a consensus price target of $199.53, indicating a potential upside of 68.13%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Palvella Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Palvella Therapeutics had 6 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Palvella Therapeutics and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Palvella Therapeutics' score of 0.46 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Palvella Therapeutics beats PureTech Health on 9 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Sarepta Therapeutics presently has a consensus target price of $24.81, indicating a potential upside of 43.74%. Given Sarepta Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Sarepta Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.08
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PureTech Health has lower revenue, but higher earnings than Sarepta Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.83	-$713.41M	-$0.96	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

In the previous week, Sarepta Therapeutics had 2 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Sarepta Therapeutics and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Sarepta Therapeutics' score of 0.61 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PureTech Health has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
PureTech Health	N/A	N/A	N/A

Sarepta Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 5.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Sarepta Therapeutics beats PureTech Health on 9 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

0.0% of PureTech Health shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Syndax Pharmaceuticals presently has a consensus target price of $42.55, indicating a potential upside of 116.96%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Syndax Pharmaceuticals is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PureTech Health has lower revenue, but higher earnings than Syndax Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	10.08	-$285.42M	-$2.79	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

In the previous week, Syndax Pharmaceuticals had 5 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 1 mentions for PureTech Health. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat PureTech Health's score of 0.72 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PureTech Health has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. PureTech Health's return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
PureTech Health	N/A	N/A	N/A

Syndax Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Summary

PureTech Health beats Syndax Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does PureTech Health compare to Septerna?

Septerna (NASDAQ:SEPN) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Septerna currently has a consensus target price of $45.78, suggesting a potential upside of 25.18%. Given Septerna's stronger consensus rating and higher possible upside, research analysts plainly believe Septerna is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Septerna has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$72.26M	22.81	-$48.88M	-$0.81	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Septerna has a beta of 2.39, suggesting that its stock price is 139% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

In the previous week, Septerna had 2 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Septerna and 1 mentions for PureTech Health. Septerna's average media sentiment score of 1.16 beat PureTech Health's score of 0.72 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.0% of PureTech Health shares are held by institutional investors. 5.8% of Septerna shares are held by insiders. Comparatively, 5.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

PureTech Health has a net margin of 0.00% compared to Septerna's net margin of -49.88%. PureTech Health's return on equity of 0.00% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
PureTech Health	N/A	N/A	N/A

Summary

Septerna beats PureTech Health on 10 of the 15 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$424.04M	$3.45B	$6.44B	$12.38B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	N/A	19.75	24.66	23.99
Price / Sales	91.01	330.63	528.55	106.76
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.38	8.29	10.83	6.50
Net Income	-$109.74M	$23.85M	$3.56B	$336.88M
7 Day Performance	N/A	2.87%	0.93%	-0.16%
1 Month Performance	N/A	2.19%	0.36%	0.76%
1 Year Performance	-2.13%	55.48%	29.66%	28.49%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	0.7708 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100
AMLX Amylyx Pharmaceuticals	2.0649 of 5 stars	$15.05 -0.9%	$23.00 +52.8%	+226.1%	$1.69B	$87.37M	N/A	200	News Coverage
PVLA Palvella Therapeutics	2.7013 of 5 stars	$110.12 -5.5%	$199.53 +81.2%	+426.5%	$1.67B	$42.81M	N/A	N/A	Insider Trade
SRPT Sarepta Therapeutics	3.0053 of 5 stars	$15.78 +0.1%	$24.77 +57.0%	-8.5%	$1.66B	$2.20B	N/A	1,372
SNDX Syndax Pharmaceuticals	3.6454 of 5 stars	$18.55 +0.4%	$42.55 +129.4%	+113.4%	$1.64B	$217.17M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTC) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. AMLX, PVLA, SRPT, SNDX, and SEPN

How does PureTech Health compare to Amylyx Pharmaceuticals?

Summary

How does PureTech Health compare to Palvella Therapeutics?

Summary

How does PureTech Health compare to Sarepta Therapeutics?

Summary

How does PureTech Health compare to Syndax Pharmaceuticals?

Summary

How does PureTech Health compare to Septerna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. AMLX, PVLA, SRPT, SNDX, and SEPN

How does PureTech Health compare to Amylyx Pharmaceuticals?

Do insiders and institutionals have more ownership in PRTC or AMLX?

Does the media favor PRTC or AMLX?

Is PRTC or AMLX more profitable?

Do analysts rate PRTC or AMLX?

Which has more risk & volatility, PRTC or AMLX?

Which has higher earnings and valuation, PRTC or AMLX?

Summary

How does PureTech Health compare to Palvella Therapeutics?

Is PVLA or PRTC more profitable?

Do insiders & institutionals believe in PVLA or PRTC?

Which has higher valuation & earnings, PVLA or PRTC?

Which has more risk & volatility, PVLA or PRTC?

Do analysts recommend PVLA or PRTC?

Does the media favor PVLA or PRTC?

Summary

How does PureTech Health compare to Sarepta Therapeutics?

Do analysts recommend SRPT or PRTC?

Which has preferable earnings and valuation, SRPT or PRTC?

Does the media favor SRPT or PRTC?

Is SRPT or PRTC more profitable?

Which has more volatility & risk, SRPT or PRTC?

Do institutionals and insiders have more ownership in SRPT or PRTC?

Summary

How does PureTech Health compare to Syndax Pharmaceuticals?

Do insiders and institutionals believe in SNDX or PRTC?

Do analysts recommend SNDX or PRTC?

Which has higher valuation & earnings, SNDX or PRTC?

Does the media prefer SNDX or PRTC?

Is SNDX or PRTC more profitable?

Which has more risk and volatility, SNDX or PRTC?

Summary

How does PureTech Health compare to Septerna?

Do analysts recommend SEPN or PRTC?

Which has stronger valuation & earnings, SEPN or PRTC?

Which has more risk & volatility, SEPN or PRTC?

Does the media prefer SEPN or PRTC?

Do insiders & institutionals have more ownership in SEPN or PRTC?

Is SEPN or PRTC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools